AR positive

News alerts, weekly reports and conference planners

Entrez ID:

367

Related biomarkers:

‹

›

AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	leuprolide acetate Sensitive: A2 - Guideline leuprolide acetate Sensitive : A2	leuprolide acetate Sensitive: A2 - Guideline leuprolide acetate Sensitive : A2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	enzalutamide Sensitive: C2 – Inclusion Criteria enzalutamide Sensitive : C2	enzalutamide Sensitive: C2 – Inclusion Criteria enzalutamide Sensitive : C2
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2
AR positive	Estrogen Receptor Positive Breast Cancer	AR positive	Estrogen Receptor Positive Breast Cancer	enobosarm Sensitive: C2 – Inclusion Criteria enobosarm Sensitive : C2	enobosarm Sensitive: C2 – Inclusion Criteria enobosarm Sensitive : C2
AR positive	Breast Cancer	AR positive	Breast Cancer	GT0918 Sensitive: C2 – Inclusion Criteria GT0918 Sensitive : C2	GT0918 Sensitive: C2 – Inclusion Criteria GT0918 Sensitive : C2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	abiraterone acetate Sensitive: C3 – Early Trials abiraterone acetate Sensitive : C3	abiraterone acetate Sensitive: C3 – Early Trials abiraterone acetate Sensitive : C3
AR positive	Ovarian Cancer	AR positive	Ovarian Cancer	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3
AR positive	Prostate Cancer	AR positive	Prostate Cancer	XY123 Sensitive: C4 – Case Studies XY123 Sensitive : C4	XY123 Sensitive: C4 – Case Studies XY123 Sensitive : C4
AR positive	Urothelial Cancer	AR positive	Urothelial Cancer	silodosin Resistant: D – Preclinical silodosin Resistant : D	silodosin Resistant: D – Preclinical silodosin Resistant : D
AR positive	Breast Cancer	AR positive	Breast Cancer	FT-6876 Sensitive: D – Preclinical FT-6876 Sensitive : D	FT-6876 Sensitive: D – Preclinical FT-6876 Sensitive : D
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	apalutamide Sensitive: D – Preclinical apalutamide Sensitive : D	apalutamide Sensitive: D – Preclinical apalutamide Sensitive : D
AR positive	Prostate Cancer	AR positive	Prostate Cancer	abemaciclib Sensitive: D – Preclinical abemaciclib Sensitive : D	abemaciclib Sensitive: D – Preclinical abemaciclib Sensitive : D
AR positive	Prostate Cancer	AR positive	Prostate Cancer	GT0918 Sensitive: D – Preclinical GT0918 Sensitive : D	GT0918 Sensitive: D – Preclinical GT0918 Sensitive : D
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	HC-1119 Sensitive: D – Preclinical HC-1119 Sensitive : D	HC-1119 Sensitive: D – Preclinical HC-1119 Sensitive : D
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	ceritinib Sensitive: D – Preclinical ceritinib Sensitive : D	ceritinib Sensitive: D – Preclinical ceritinib Sensitive : D
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	enzalutamide + ceritinib Sensitive: D – Preclinical enzalutamide + ceritinib Sensitive : D	enzalutamide + ceritinib Sensitive: D – Preclinical enzalutamide + ceritinib Sensitive : D
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	enzalutamide + KRLS-017 Sensitive: D – Preclinical enzalutamide + KRLS-017 Sensitive : D	enzalutamide + KRLS-017 Sensitive: D – Preclinical enzalutamide + KRLS-017 Sensitive : D
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	VNLG-152R Sensitive: D – Preclinical VNLG-152R Sensitive : D	VNLG-152R Sensitive: D – Preclinical VNLG-152R Sensitive : D
AR positive	Prostate Cancer	AR positive	Prostate Cancer	erdafitinib Sensitive: D – Preclinical erdafitinib Sensitive : D	erdafitinib Sensitive: D – Preclinical erdafitinib Sensitive : D
AR positive	Prostate Cancer	AR positive	Prostate Cancer	enzalutamide + Debio 1347 Sensitive: D – Preclinical enzalutamide + Debio 1347 Sensitive : D	enzalutamide + Debio 1347 Sensitive: D – Preclinical enzalutamide + Debio 1347 Sensitive : D
AR positive	Prostate Cancer	AR positive	Prostate Cancer	erdafitinib + Debio 1347 Sensitive: D – Preclinical erdafitinib + Debio 1347 Sensitive : D	erdafitinib + Debio 1347 Sensitive: D – Preclinical erdafitinib + Debio 1347 Sensitive : D

AR positive

Associations